

# Med-X, Inc. Secures \$100 Million Expansion Capital Commitment from Global Emerging Markets (GEM)

NEWS PROVIDED BY

**Med-X, Inc.** →

Aug 06, 2021, 19:47 ET

SHARE THIS ARTICLE



LOS ANGELES, Aug. 6, 2021 /PRNewswire/ -- Today, **Med-X, Inc.** (MED-X) announced a \$100 million capital commitment from **GEM Global Yield, LLC SCS** (GGY), a Luxembourg-based private alternative investment group. Under the agreement, GGY will provide MED-X with a Share Subscription Facility of up to \$100 million for a 36-month term following the public listing of MED-X's common stock.



Med-X will control the timing and maximum number of drawdowns and under this agreement can put a drawdown notice for up to \$10MM worth of shares on the first day of trading. Concurrent with a public listing Med-X will issue warrants to GEM to purchase up to 4.0% of the common stock of the company. Med-X's flagship division, **Nature-Cide**, has developed a line of all-natural professional pest control applications. One of its pest control solutions for Vector Control, is continuously being tested by third parties **with astounding recorded results**. The products are set for expansion, from major distribution partners in various regions around the globe.

"GEM's equity investment solidifies our business model as well as our long-term financial goals while reinforcing and furthering our mission to the world stage", states founder and COO Matthew Mills. "So far, we've been very successful with self-underwriting our **Regulation A+ Offering**, which has generated investments from more than 3,600 individuals over the last 4 years. This new \$100MM capital commitment should allow the Company to advance on its Mergers & Acquisitions strategy, while propelling the brands in a manner where our mission of **"Making a difference every day"** will move to a whole new level", states Mills.

## About Med-X, Inc.

Med-X, Inc. is a Nevada corporation formed in February 2014 to support the fast-paced environmentally friendly green scene products and services sectors, with its **Nature-Cide**, **Thermal-Aid** and **Malibu Brands** divisions as well as the emerging hemp and cannabis industry through such activities as compound identification and extraction of the identified cannabidiol (CBD) compounds for the present medical industry demand.

For more information regarding Med-X, Inc., please visit [www.medx-rx.com](http://www.medx-rx.com), email [info@medx-rx.com](mailto:info@medx-rx.com) or call 818-349-2870

## About The GEM Global Yield, LLC SCS Group

### About GEM

Global Emerging Markets ('GEM') is a \$3.4 billion, alternative investment group with offices in Paris, New York and Nassau (Bahamas). GEM manages a diverse set of investment vehicles focused on emerging markets and has completed over 440 transactions in 70 countries. Each investment vehicle has a different degree of operational control, risk-adjusted return, and liquidity profile. The family of funds and investment vehicles provide GEM and its partners with exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities, and select venture investments. For more information: <https://www.gemny.com>

### **GEM Contact:**

**Jean-Luc Bonnefoy:** [jbonnefoy@gemny.com](mailto:jbonnefoy@gemny.com)

### **Med-X Contact**

**Matthew Mills:** [matt@medx-rx.com](mailto:matt@medx-rx.com)

## DISCLAIMER AND FORWARD-LOOKING STATEMENTS

The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of **MED-X, INC.** involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the **Regulation A+ Offering Circular** Securities Exchange Commission filings before making any investment in the Company.

This article may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.

SOURCE Med-X, Inc.

### Related Links

<https://medx-rx.com/>

## Contact Cision

Cision Distribution 888-776-0942  
from 8 AM - 9 PM ET

Contact Us



## Products

Cision Communication Cloud®  
For Marketers  
For Public Relations  
For IR & Compliance  
For Agency  
For Small Business  
All Products

## About

About PR Newswire  
About Cision  
Become a Publishing Partner  
Become a Channel Partner  
Careers  
COVID-19 Resources  
Accessibility Statement

Global Sites

## My Services

All New Releases  
Online Member Center  
ProfNet